Status:
UNKNOWN
Camrelizumab Combined With Apatinib Mesylate
Lead Sponsor:
Henan Cancer Hospital
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors
Detailed Description
According to current studies, the combination of camrelizide and apatinib mesylate has significant efficacy and controllable toxicity in the treatment of solid tumors. This study adopted camrelizumab...
Eligibility Criteria
Inclusion
- Age: ≥18 years old, male or female;
- ECOG score is 0\~2;
- Patients with solid tumors confirmed by pathology or histology;
- At least one measurable lesion (according to RECIST V 1.1);
- For patients who have failed first-line or second-line treatment or who cannot tolerate standard treatment regimens for solid tumors.
- Estimated survival ≥3 months;
- Patients who have used immunosuppressants or antiangiogenic drugs in the past are not excluded;
- For women who have not undergone menopause or surgical sterilization, agree to abstain from sex or use an effective contraceptive method during treatment and for at least 7 months after the last dose given in study treatment;
- Researchers think they can benefit;
- Voluntarily participate in the study and sign the informed consent;
Exclusion
- Pregnant or lactating women;
- Except patients with contraindications to camrelizumab and/or apatinib mesylate, that is, those allergic to camrelizumab and its excipients; Allergic to apatinib mesylate should be prohibited; It should be contraindication for patients with active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension beyond drug control within 30 days after major surgery, class III-IV cardiac insufficiency (NYHA standard), and severe hepatic or renal insufficiency (Class 4).
- Those deemed unsuitable for inclusion by doctors;
- The researchers determined there was a high risk that the tumor would invade important blood vessels and cause fatal hemorrhages during the follow-up study
Key Trial Info
Start Date :
May 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05380986
Start Date
May 20 2022
End Date
May 1 2025
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Tumor Hospital
Henan, China